Abbott ABT Established Pharmaceuticals — Goodwill, non-deductible

Other segment segments

Questions, answered.

What is Abbott's established pharmaceuticals — goodwill, non-deductible?

Abbott (ABT) reported established pharmaceuticals — goodwill, non-deductible of $2.7B in Q1 2026.

How has Abbott's established pharmaceuticals — goodwill, non-deductible changed year-over-year?

Abbott's established pharmaceuticals — goodwill, non-deductible increased by 3.8% year-over-year, from $2.6B to $2.7B.

What is the long-term trend for Abbott's established pharmaceuticals — goodwill, non-deductible?

Over 4 years (2021 to 2025), Abbott's established pharmaceuticals — goodwill, non-deductible has grown at a -1.8% compound annual growth rate (CAGR), from $11.5B to $10.7B.

What does established pharmaceuticals — goodwill, non-deductible mean?

The amount of non-tax-deductible goodwill allocated to the Established Pharmaceuticals business segment.

How do you interpret established pharmaceuticals — goodwill, non-deductible?

An increase suggests recent acquisitions at a premium, while a decrease may indicate impairment charges or the write-down of asset values. High levels relative to segment equity may signal future risk of impairment if the segment's growth prospects decline.

How does established pharmaceuticals — goodwill, non-deductible compare across companies?

Peers in the pharmaceutical and medical device sectors typically report goodwill by segment; non-deductible portions are common in large-scale M&A activity and are compared against total segment assets to assess balance sheet health.